|
|
||||||||
Department of Pathology and Laboratory Medicine, University of Rochester School of Medicine and Dentistry, Rochester, New York 14642
Submitted 30 June 2003 ; accepted in final form 11 February 2004
Triglyceride-rich lipoprotein (TRL) production was studied in Zucker diabetic fatty (ZDF) rats, a model of insulin-resistant type 2 diabetes progression. TRL production was measured in vivo by blocking catabolism with Triton WR-1339. Ten-week ZDF rats are hyperinsulinemic with increased TRL production [both triglyceride and apolipoprotein B (apoB)]. Twenty-week ZDF rats are insulinopenic, and TRL production is similar to lean controls. Insulin infusion suppresses glucose and free fatty acids in 10- and 20-wk ZDF rats. Increased TRL production is not reduced by insulin in 10-wk rats; however, at 20 wk, TRL production is suppressed by insulin. In vitro studies with hepatocytes derived from 10-wk ZDF rats showed minimal insulin dose effects on apoB secretion compared with the response and sensitivity of hepatocytes derived from 20-wk ZDF and control lean rats. Hepatic sterol regulatory-binding protein (SREBP)-1c mRNA levels are increased at 10 wk but return to control levels at 20 wk. ApoB mRNA levels are similar to lean controls at 10 and 20 wk. The following two mechanisms for hypertriglyceridemia associated with hyperinsulinemia are suggested: increased TRL synthesis and loss of TRL suppression. Increased triglyceride production in hyperinsulinemic rats likely relates to increased expression of SREBP-1c, whereas increased apoB production involves posttranscriptional processes.
hyperinsulinemic diabetes; insulinopenic diabetes; apolipoprotein b metabolism; triglyceride-rich lipoprotein production
This article has been cited by other articles:
![]() |
H. N. Ginsberg and E. A. Fisher The ever-expanding role of degradation in the regulation of apolipoprotein B metabolism J. Lipid Res., April 1, 2009; 50(Supplement): S162 - S166. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Agius Targeting Hepatic Glucokinase in Type 2 Diabetes: Weighing the Benefits and Risks Diabetes, January 1, 2009; 58(1): 18 - 20. [Full Text] [PDF] |
||||
![]() |
D. V. Chirieac, N. O. Davidson, C. E. Sparks, and J. D. Sparks PI3-kinase activity modulates apo B available for hepatic VLDL production in apobec-1-/- mice Am J Physiol Gastrointest Liver Physiol, September 1, 2006; 291(3): G382 - G388. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |